Skip to main content

Table 3 Resolution of symptoms of COVID-19

From: Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial

Symptoms

Time to resolution of symptoms

Resolution of symptoms

Treatment (n = 36)

Control (n = 36)

Median

(95%CI)

Median

(95%CI)

HRa

95%CI

p-value

All symptoms

8

(5–10)

8

(7–13)

1.18

(0.68 to 2.05)

0.562

Cough

5

(3–8)

8

(4–8)

1.23

(0.74 to 2.03)

0.427

Runny nose

0

(0–3)

2

(0–5)

1.32

(0.82 to 2.13)

0.251

Sore throat

0

(0–3)

0

(0–3)

1.00

(0.63 to 1.59)

0.997

Smell disturbance

0

(0–0)

0

(0–0)

1.23

(0.76 to 1.99)

0.391

Taste disturbance

0

(0–1)

0

(0–0)

0.96

(0.60 to 1.53)

0.864

Muscle pain

0

(0–1)

0

(0–0)

0.81

(0.50 to 1.31)

0.388

Headache

0

(0–0)

0

(0–0)

1.25

(0.78 to 2.02)

0.354

Fever

0

(0–1)

0

(0–1)

0.90

(0.57 to 1.43)

0.650

Dyspnea

0

(0–0)

0

(0–0)

0.97

(0.61 to 1.54)

0.888

Block nose

0

(0–0)

0

(0–0)

1.08

(0.68 to 1.73)

0.733

Diarrhea

0

(0–0)

0

(0–0)

1.03

(0.65 to 1.65)

0.888

Chest pain

0

(0–0)

0

(0–0)

1.06

(0.66 to 1.69)

0.811

Fatigue

0

(0–0)

0

(0–0)

1.19

(0.73 to 1.92)

0.488

Sneezing

0

(0–0)

0

(0–0)

1.05

(0.66 to 1.67)

0.843

Vomiting

0

(0–0)

0

(0–0)

1.03

(0.65 to 1.64)

0.906

  1. aHazard ratio for resolution of symptoms was estimated by the Cox proportional-hazard model